• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 15.85
  • VXN 20.63
  • VXO 18.01
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)

Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:

Indicator Windows:

ENZ (Enzo Biochem Inc. ($0.01 Par Value))
Last Trade 3.23 Dividend/Share 0 PE Ratio null
Date May 24-2019 Dividend Yield 0.000 Return on Assets -24.52
Change -0.01 ExDividend Date 0 Return on Capital null
Bid null Latest EPS -0.21 Price/Sale 2.356
Ask null LatestEPS Date 2018-07-31 Price to Book 2.26
Volume null EPS ttm 0.000 Institutional % 89
Avg Volume 0.21M Shares Outstanding 47.24M Insider % null
Open 3.25 Float 41.56M Short Ratio 4.950
Prev Close 3.24 Return On Equity -31.19 5 Year Change % -0.159
High 3.29 Consensus EPS 0 2 Year Change % -0.644
Low 3.19 No. of Estimate 0.000 1 Year Change % -0.506
52 Week High 6.76 EPS Surprise $ null YTD Change % 0.154
52 Week Low 2.32 EPS Surprise Percent 0 6 Month Change % 0.016
52 Week Change -50.612 EBITDA 0M 3 Month Change % -0.093
50 Day MA 3.26 Revenue 0M 1 Month Change % -0.056
200 Day MA Gross Profit 0M 5 Day Change % -0.108
Market Cap 152.59M Cash 0M 30 Day Change % -0.061
Beta 1.422742 Debt 0M Stock Exchange New York Stock Exchange
Sector Healthcare Revenue Per Share 0 Short Interest 1311576
Short Date 2019-04-15 Revenue Per Employee 0 Short Ratio 4.950
Data courtesy of IEX
Company Profile

Enzo Biochem, Inc., a life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Enzo Life Sciences, Enzo Clinical Labs, and Enzo Therapeutics. The Enzo Life Sciences segment manufactures, develops, and markets functional biology and cellular biochemistry products and tools to research and pharmaceutical customers. It offers products applied in the fields of antibiotics, autophagy, cancer, cell cycle, cell death, cell signaling, cell trafficking, genomics/molecular biology, immunology, inflammation, lipid signaling, neurobiology, protein degradation, ROS/RNS, and stress/heat shock. The Enzo Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It also operates a full-service clinical laboratory, a network of 30 patient service centers, a stand alone or rapid response laboratory, and a full-service phlebotomy department. The Enzo Therapeutics segment engages in the research and development of various therapeutic drug candidates based on cell signaling, immune regulation, and gene regulation for the treatment of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem, Inc. sells its products through direct sales force and distributors in the United States, Switzerland, the United Kingdom, Belgium, and Germany. The company was founded in 1976 and is headquartered in New York, New York.